New combo tackles rare, aggressive lymphoma
NCT ID NCT04139304
First seen Jun 02, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This early study tests adding daratumumab, an antibody that targets a protein on cancer cells, to standard chemotherapy for people with newly diagnosed plasmablastic lymphoma, a rare and fast-growing cancer. The trial includes up to 15 participants, with or without HIV. The main goal is to see if the combination is feasible and safe, not yet to prove it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANN ARBOR STAGE IV DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Miami Miller School of Medicine
RECRUITINGMiami, Florida, 33136, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of North Carolina - Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab (a targeted antibody) plus a combination of chemotherapy drugs (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)
What this could lead to
If successful, this could point toward a more effective first treatment for plasmablastic lymphoma, a rare and aggressive cancer.
What could go wrong
This is a very early, small feasibility study with only 15 participants. It is not designed to prove the treatment works, only that it can be given. Side effects from the added drug and chemo are expected.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.